INTERNATIONAL-HOLDINGS
20.5.2020 19:45:13 CEST | Business Wire | Press release
QuantLase Imaging Lab, the medical-research arm of the Abu Dhabi Stock Exchange-listed International Holdings Company (IHC), announced that it has developed novel equipment which enables for much faster mass screenings, with test results available in seconds and allowing testing on a wider scale. This break-through will enable ‘Mass-scale screening’, changing the whole dimension of tracing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200520005743/en/
AbdulRahman bin Mohammed Al Owais, Minister of Health and Prevention, expressed hope over the discovery saying: “We are always following innovations related to the early and rapid detection of Covid–19. The government is keen on supporting initiatives that help the healthcare system in the UAE. Health officials have been closely monitoring the progress of trials with QuantLase in order to test this equipment. We are proud to see a technology that works and that will help to protect our people better.”
“The equipment, which uses a CMOS detector, will enable mass-scale screening with results made available in seconds,” said Dr Pramod Kumar, who leads the team of researchers at the lab which has been studying the change in cell structure of the virus-infected blood.
“In fact, our laser-based DPI [Diffractive Phase Interferometry] technique, based on optical-phase modulation, is able to give a signature of infection within a few seconds. What’s more, it is user-friendly, non-invasive and low-cost. We believe it will be a game-changer in tackling the spread of the coronavirus.”
Explaining the critical role of artificial intelligence (AI) in the diagnostic system, Dr Kumar said that an advanced AI image-analysis model predicts the outcome of each image with precision, speed and scale. This is especially critical in large-scale testing programs, where a massive number of images needs to be analysed with accuracy and efficiency. The lab is using G42, a leading AI and Cloud Computing company, to further enhance the laser program.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005743/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Andersen Consulting styrker sin platform med samarbejdsvirksomheden Ambit Iberia12.3.2026 05:55:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Ambit Iberia, et konsulentfirma, der specialiserer sig i digitale og regulatoriske løsninger til life science-sektoren. Ambit Iberia, der blev stiftet i 2003, har hovedsæde i Spanien og leverer integrerede løsninger inden for rådgivning, teknologi og rekruttering til medicinal-, bioteknologi- og medtechvirksomheder. Virksomheden hjælper kunder med at opfylde skiftende standarder for kvalitet, compliance og lovgivning gennem ydelser, der spænder over regulatoriske anliggender, dataintegritet, validering af it-systemer og digital transformation. Med mere end 20 års brancheerfaring tilbyder Ambit Iberia også ydelser inden for human capital og executive search, der forbinder organisationer med specialiserede fagfolk og topledertalenter, hvilket øger effektiviteten og fremmer bæredygtig vækst i et stærkt reguleret miljø. "Vores fokus har altid været at levere speciali
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 03:14:00 CET | Press release
Transaction increases MidOcean’s equity exposure to premier Australian LNG project Adds incremental uncontracted LNG volumes, enhancing portfolio optimization and marketing flexibility Planning future collaborations, exploring further transactions and opportunities with JERA across other assets globally with the aim of creating a future strategic alliance MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ich
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 16:34:00 CET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom